IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Sun Pharma and Lupin receive FDA approvals for generic Cymbalta

7:34 AM MST | December 12, 2013 | Natasha Alperowicz

Sun Pharmaceutical Industries (Mumbai) and Lupin (Mumbai), two leading pharma producers for the global markets, announced today that their US subsidiaries have gained FDA approvals for duloxetine hydrochloride delayed release drug, the generic version of the antidepressant  Cymbalta.  Cymbalta delayed-release capsule 20, 30 and 60 mg is an Eli Lilly product with last year’s sales in the United States approaching $5.5 billion.   Sun Pharma in the year ended 31 March 2013 reported sales of $2.1 billion of which $1.1 billion were in the US...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa